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Summary
Purpose: To assess the use of specialised medical epilepsy services by people with
learning disabilities (LD) and epilepsy in a community healthcare setting, to compare
medical epilepsy care in this group to current management guidelines, and to contrast
important outcomes with those achieved in different healthcare settings.
Methods: Postal survey with a carer completed questionnaire addressed to all adults
with epilepsy registered on an LD register in Sheffield, UK (n = 442).
Results: An analysis based on 225 returned questionnaires revealed that 22.7% of
individuals with LD and epilepsy had been free of seizures for over 1 year. 95.1% were
taking antiepileptic drugs (AEDs), 46.2% had had an EEG, and 41.3% a brain scan. 53.3%
of diagnoses had been made by epilepsy experts, 38.7% of individuals with LD and
epilepsy were under specialist review. Although patients with more severe epilepsy
were more likely to be under specialist care, 60.6% of patients with ongoing seizures,* Corresponding author. Tel.: +44 114 2268763; fax: +44 114 2713158.
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57.9% with major seizures and 68.7% of individuals taken to hospital with prolonged
had no access to specialist advice.
Conclusion: The proportion of people with LD who achieved seizure-control in the
described population was lower than in all previously reported studies of LD patient
groups. The poor outcome in terms of seizure-control, the lack of access to the
epilepsy specialist service, and the apparent under-utilisation of investigations
indicate that there are grounds for serious concern about this community model
of medical epilepsy care for people with LD.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.In the last decade, the provision of community and
hospital medical services has undergone rapid
changes in many developed countries. In the UK,
a number of recent healthcare reforms were
intended to reduce the role of costly (and typically
hospital-based) specialist service providers and to
increase the scope of community medical services.
As traditional referral routes and treatment respon-
sibilities are redesigned and redistributed, ‘‘patient
journeys’’ have become a particular focus of inter-
est. Ideally, historical arrangements would not only
be replaced by less expensive systems, but also by
organisational structures, which would lead to
improvements in the selection of patients referred
to specialist services. This would focus limited spe-
cialist care resources on those patients who could
benefit most.
Optimal ‘‘patient journeys’’ probably matter
most in conditions or situations where patients
may not be able to seek out the most appropriate
services for themselves, for instance in the area of
healthcare provision for people with learning dis-
abilities (LD).
In some ways, the disestablishment of specialised
LD residential care facilities has led the way for
changes in many other areas of healthcare provi-
sion. For instance, in one area in the UK, 54% of
people with LD lived in specialist hospital accom-
modation in 1983, and only 6% in 1995.1 This means
that the examination of an established model of
community care for people with LDmay offer impor-
tant insights into the potential benefits and pitfalls
of similar healthcare delivery models in other areas.
The arrangements put in place for people with LD
in Sheffield, UK, in the 1970s placed particular
emphasis on the integration of people with LD into
general healthcare services. In this model, most
medical care needs are addressed in a community
setting, and the General Practitioner (GP) becomes
the primary medical point of contact. Usual care is
supplemented by multidisciplinary Community
Learning Disability Teams covering certain geogra-
phical areas and consisting of physiotherapists,
occupational therapists, psychologists, speech and
language therapists, social workers and specialistnurses in LD. Although these teams have no direct
referral rights to epilepsy specialist services they
are intended to ensure that all of the patients’
healthcare needs are met, using the GP to secure
access to specialist advice if necessary. The Com-
munity Learning Disability Teams belong to the Joint
Learning Disabilities Service (JLDS), which is part of
the community mental health service. It retains a
small medical LD service staffed with one psychia-
trist with an interest in LD and a seven-bedded
assessment and treatment unit (ATU) with a primar-
ily psychiatric focus. It is the remit of the ATU to
provide assessment and treatment of individuals
with significant LD with challenging behaviour or
comorbid psychiatric disorders. There is no access to
EEG or video-telemetry. The JLDS also has access to
five beds on a general psychiatric ward for people
with mental disorders and less severe LD. Finally
there are 15 designated beds for individuals with LD
and complex health needs, which form the health
component of an integrated respite service.
The hospital-based specialist epilepsy service
consists of four consultant neurologists with access
to relevant investigations including magnetic reso-
nance imaging under general anaesthesia and epi-
lepsy specialist nurses (who will only advise patients
under the current care of a neurologist). Although
the National Health Service is essentially the only
purchaser of medical services for individuals with
LD, the healthcare providers described here belong
to different organisation with independent budgets
(community mental health services, medical hospi-
tal services and several primary care organisations).
The introduction of this model of community care
was supported by a database (Sheffield Case Regis-
ter) held by the local provider of mental health
services which shares information with social and
educational services and contains details of people
with more severe LD.
We conducted a postal survey to find out more
about the health services utilisation of people with
LD and epilepsy on the Sheffield Case Register, and
how service use relates to current management
guidelines for epilepsy.2,3 We also examined
whether patients with the greatest need have
86 M. Reuber et al.access to the local specialist epilepsy services.
Finally, we assessed the quality of epilepsy services
for people with LD and epilepsy by comparing treat-
ment outcomes in Sheffield residents with those in
similar populations treated in other healthcare set-
tings.4—13Methods and patients
The findings of this survey are based on an ‘‘Epilepsy
Questionnaire’’ specifically designed for this study
by a multidisciplinary group comprising social ser-
vices managers, nurse specialists in epilepsy and
learning disabilities, and a neurologist with a parti-
cular interest in epilepsy. The survey was approved
as a service evaluation by the clinical audit depart-
ment of the Sheffield Care Trust. The questionnaire
was designed to be completed by carers for people
with LD. It contained a total of 19 closed questions.
Answers were elicited in tick-boxes.
The questionnaire was sent to all individuals from
the Sheffield Case Register who also had a recorded
diagnosis of epilepsy. The Register contains details
of people with LD who meet at least one additional
criterion (in need of a developmental curriculum,
regular users of LD services, clinical condition which
is a recognised cause of LD, requiring support from
residential, day or community services because of
LD). Individuals with a diagnosis of mild mental
retardation (IQ 50—70) are not registered. At the
time of the study the register contained details of
1934 Sheffield residents with LD above the age of 18.
An additional diagnosis of epilepsy was recorded in
442. The diagnoses of LD and epilepsy had been
made by a doctor in primary or secondary care.
The questionnaire was piloted in 10 individuals.
The questionnaire was only sent out once. No
attempts were made to remind or chase up non-
responders. Questionnaires were only analysed if
the person completing the questionnaire confirmed
the diagnosis of epilepsy on the questionnaire.
Variables were compared using the x2-test. A
two-tailed p < 0.05 was considered significant.Figure 1 Frequency distribution of ‘‘major’’ and
‘‘minor’’ epileptic seizures over the preceding year in
225 adults with LD in epilepsy. Only 22.7% had been
completely seizure-free for at least 1 year.Results
The questionnaire was addressed to 442 adults with
LD and epilepsy living in Sheffield, UK. Themean age
was 43.5 (SD 16.1, range 18—86 years), 53.3% of
addressees were male, the most frequently repre-
sented ethnic groups were White (91.2%), Pakistani
(3.9%) and Black (0.9%). 44.6% lived in residential
care or supported living, 43.2% with carers, 6.9%
on their own, 1.2% were married or living with apartner, residential arrangements were unknown for
4.2%. Questionnaires providing information on 236/
442 (53.4%) people with LD and epilepsy were
returned. The diagnosis of epilepsy was denied on
eleven questionnaires, this analysis is thus based on
225/442 returns (50.9%).
Description of seizure disorders
Sixty percent of people with LD and epilepsy were
reported as having had ‘‘major seizures’’ in the last
year (described in the questionnaire as ‘‘for exam-
ple blacking out, going stiff and jerking, falling
down’’). 62.7% had ‘‘minor seizures’’ (‘‘for example
funny turns, blank spells, confusion’’). Only 22.7%
had not had any seizures over the last year (Fig. 1).
15.6% had to attend a hospital Accident and Emer-
gency Department at least once over the preceding
year because seizures would not stop, 5.3%
attended more often. 34.2% of respondents
reported seizures from sleep, 28.0% denied sleep-
related seizures, and 37.8% stated that they were
unsure about seizures from sleep.
Antiepileptic drug treatment
The number of antiepileptic drugs (AEDs) used as
regular medication by individuals with LD and epi-
lepsy ranged from nil to five (median 1). 4.9% of
people with LD and epilepsy were described as not
taking any of the listed AEDs, 48.4% were receiving
AED monotherapy, 46.7% AED combination therapy.
The most commonly used drugs were carbamaze-
pine (50.2%), sodium valproate (39.6%), phenytoin
(18.2%), levetiracetam (13.3%), lamotrigine (8.4%),
phenobarbitone (6.7%), clobazam (5.8%), topira-
mate (5.8%). Acetazolamide, clonazepam, ethosux-
imide, gabapentin, oxcarbazepine, pregabaline,
tiagabine, vigabatrin and zonisamide were also used
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Table 1 Cross tabulation of indicators of access to regular or specialist epilepsy advice and markers of complexity of
epilepsy (severity or difficulty with seizure management)
N = 225 Under expert review Seen by epilepsy nurse  annual epilepsy review
Yes
(N = 80) (%)
No
(N = 145) (%)
Yes
(N = 77) (%)
No
(N = 148) (%)
Yes
(N = 158) (%)
No
(N = 67) (%)
Seizure-free 1 year 14.3 39.4 7.8 43.7 17.7 52.3
Major seizures in 1 year 75.0 57.9 77.9 56.8 71.5 46.3
A&E with seizure in 1 year 31.3 15.9 31.2 16.2 24.1 14.9
Emergency medication 37.5 22.1 33.8 24.3 32.9 14.9
AED combination therapy 64.1 40.4 71.6 37.1 54.5 35.0
Possible AED side-effects 82.5 67.6 87.0 65.5 77.8 61.2
‘‘Newer’’ AED(s) 52.5 11.7 57.1 10.1 34.8 6.0
Brain scan 52. 35.7 57.1 33.6 45.2 33.3
EEG 55.0 41.4 61.0 38.5 48.1 41.8
Table 2 Cross tabulation of indicators of seizure severity and epilepsy service input
N = 225 Seizure-free 1 year Major seizures in 1 year A&E with seizure in1 year
Yes
(N = 51) (%)
No
(N = 174) (%)
Yes
(N = 144) (%)
No
(N = 81) (%)
Yes
(N = 48) (%)
No
(N = 177) (%)
Emergency medication 19.6 29.9 36.8 11.1 39.6 23.9
AED combination therapy 22.2 56.2 56.2 32.4 67.4 44.0
‘‘Newer’’ AED(s) 3.9 38.8 33.3 13.5 39.6 22.6
Brain scan 33.3 44.1 47.2 31.6 50 39.4
EEG 41.2 47.7 47.2 44.4 50 45.2but by less than 5% of individuals. 26.2% received
one of the pharmacological agents licensed for use
in the UK since 1993 (described as ‘‘newer’’ AEDs in
recent epilepsy guidelines).14 Of the 27.6% of
respondents who had a supply of rectal diazepam,
buccal midazolam or both at home to interrupt
prolonged seizures (27.4% diazepam, 4.5% midazo-
lam), only 42.6% stated that they had received
training from a nurse or a doctor on how to give
this medication. Only 40% of carers of those indivi-
duals with LD and epilepsy who had been to Accident
and Emergency over the last year with a prolonged
seizure had access to emergency medication.
Interaction with general and specialist
health services
53.3% of epilepsy diagnoses had been made by a
seizure expert (neurologist or paediatrician). 46.2%
of residents stated that the person with LD and
epilepsy had had an EEG, and 41.3% that a brain
scan had been performed. 68.9% of respondents
agreed that the individual had been assessed by
an expert in secondary care (neurologist, psychia-
trist or epilepsy nurse) at some point. 60.4% had
seen a neurologist, 34.2% an epilepsy nurse, and
20.9% a psychiatrist. 70.7% stated that there had
been an epilepsy treatment review within the last
12 months, the remaining respondents said reviewswere carried out less frequently. 38.7% of indivi-
duals with LD and epilepsy were reported to be
under review in secondary care (neurologist, psy-
chiatrist or epilepsy nurse), 52.9% stated that
reviews were carried out in primary care alone
and 8.9% said that epilepsy treatment had not been
reviewed at all. Only 23.4% of respondents said they
were aware of the existence of a local Epilepsy
Action group although this group has existed since
1985 (Epilepsy Action is the largest epilepsy self-
help organisation in the UK).
Table 1 cross tabulates indicators of access to
regular or specialist epilepsy advice with markers of
epilepsy complexity. Table 2 shows a cross tabula-
tion of indicators of seizure severity and epilepsy
service input.Discussion
A rangeof studies have suggested that theprevalence
of LD in the population is around 0.5%.15 Whereas
epilepsy occurs in around one in 200 individuals in the
general population, the prevalence of epilepsy in
people with LD has been estimated as between one
in four and one in five.15 Although other socioeco-
nomic andbiological factors play an important role,16
the prevalence of epilepsy increases with the degree
of intellectual impairment and motor disability.11,15
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Table 3 Grading of recommendations by the UK National Institute of Clinical Excellence
Grade Definition
A Directly based on category I evidence (meta-analysis of randomized controlled trials (RCTs) or at least
one RCT)
B Directly based on category II evidence (at least one controlled trial without randomization or at least
one other quasi-experimental study) or extrapolated from category I evidence
C Directly based on category III evidence (non-experimental descriptive studies) or extrapolated from
category II evidence
D Directly based on category IV evidence (expert committee reports or clinical experience of respected
authorities) or extrapolated from category III evidence
N Recommendation based on NICE guideline or technology appraisal
GPP Good practice point based on the clinical experience of the Guideline Development GroupHowever, the risk of epilepsy depends most strongly
on the particular aetiology of LD.10,12,15,17 Reports
from a range of sources in the UK suggest that LD
registers have captured the population of residents
with LD increasingly well over the last 50 years.18
Given that the Sheffield LD register is intended to
capture all peoplewithmoderate or severe LD from a
resident population of 413,000 adults, contains infor-
mation on1934peoplewith LDand identifies 433with
a diagnosis of epilepsy, it appears that the partici-
pants in our survey were identified from a reasonably
complete source.
The responses to the questionnaire suggest that
the use of specialist epilepsy services and epilepsy-
related investigations in the described population of
people with LD and epilepsy fell significantly short of
published national and international consensus
guidelines for the management of the epilepsies
in adults.2,3 The recommendations in the guidelines
of the UK National Institute of Clinical Excellence
(NICE) are graded according to the level of support-
ing evidence (see Table 3). The guidelines specifi-
cally state that ‘‘people with epilepsy who have LD
should receive the same support and care as the
general population’’ (GPP). In recognition of the
particular difficulties which clinicians may face
when diagnosing or treating patients with LD and
epilepsy,19—23 the guidelines state that ‘‘the diag-
nosis of epilepsy should be made by an expert in the
epilepsies’’ (C). According to our results, just over
half of all diagnoses had been made by an epilepsy
expert. The guidelines also recognise the particular
challenges involved in the ongoing management of
people with LD and epilepsy, such as increased levels
of psychopathology, behavioural problems, side-
effects of antiepileptic drugs and carer dis-
tress.18,24—26 Although the guidelines recommend
that ‘‘the management and treatment of epilepsy
in a person who has LD should be undertaken by a
specialist, working within a multidisciplinary team’’
(C), just over one-third stated that their epilepsy
was under continuing review by an epilepsy specia-list in secondary care. One particular reason why it
might be important for people with LD and epilepsy
to be assessed by specialists in secondary care is that
access to investigations such as electro-encephalo-
graphy (EEG) (C), video-EEG (C) (considered essen-
tial in the national guidelines) is often restricted to
specialists. Less than half of the respondents to this
survey thought that any EEG investigation had been
carried out. Even fewer people with LD and epilepsy
appear to have had brain imaging although the
guidelines recommend the use of ‘‘neuroimaging
(MRI/CT) to identify structural abnormalities that
cause certain epilepsies’’ (C). The only situation in
which neuroimaging is not recommended in the
evaluation of people with epilepsy is ‘‘when a diag-
nosis of idiopathic generalised epilepsy has been
made’’ (C). Neuroimaging (especially MRI) should
be considered particularly important in the context
of LD because it may not only reveal the cause of
epileptic seizures but also establish the aetiology of
LD, potentially leading to appropriate further
screening and care (such as in neurofibromatosis
or tuberous sclerosis)27 or genetic diagnoses
enabling testing and genetic counselling of potential
carriers (for instance in cortical malformation dis-
orders).28 Annual (or more frequent) epilepsy treat-
ment reviews (as suggested by the guidelines (D))
were only reported by two thirds of respondents.
We can only speculate why specialist services and
investigations were under-utilised. There were no
formal barriers to the referral of patients with LD
and seizures to the specialist service. Further
research seems justified to find out whether the
low utilisation rates were related to the choices
of individuals with LD, low expectations of general
practitioners and carers, a perceived need to
protect scarce healthcare resources, practical
difficulties associated with the attendance of hos-
pital-based clinics or other reasons. Notably, almost
one half of the individuals under specialist care
reported that they had not had neuroimaging or
an EEG.
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Table 4 Overview of seizure outcomes in populations with LD and epilepsy4—13
Reference N Method Country Setting Percentage seizure-free > 1 year
This study 236 Q UK C: 100% 22.7
Huber et al. 4 550 R Germany S: 100% 37.6
McGrother et al. 5 2393 I UK C: 100% 32.3
Kelly et al. 6 197 R UK H: 100% 45.0
Scheepers et al. 7 37 R UK H: 100% 27.0
Deb and Joyce8 143 R UK S: 20% 27.0
C: 80%
Branford et al. 9 532 I UK C: 100% 26.0 (>3 years)
Brodtkorb et al. 10 61 R Norway S: 100% 37.7
Goulden et al. 11 33 R UK H: 100% (children) 39 (> 5 years)
Forsgren et al. 12 299 R/Q Sweden C: 100% (children) 32.0
Brorson et al. 13 74 R Sweden H: 100% (children) 39.0
Method: R, record review; I, carer interview; Q, questionnaire. Setting: C, community; S, specialist residential; H, specialist hospital.Table 1 shows that specialist care and a higher
review frequency were not allocated randomly but
offered to patients with more severe epilepsies.
However, the cross tabulation also reveals that over
60% of patients with ongoing seizures, nearly 60%
with major (probably tonic clonic) seizures and two
thirds of the patients who had been taken to hospital
with prolonged seizures had no access to specialist
advice. Only one in 10 patients under primary care
review was taking one of the ‘‘newer’’ antiepileptic
drugs although recent studies suggest that the use of
these drugs can be very beneficial in patients with
LD.3,29 Whilst the use of these AEDs is not guaran-
teed to lead to an increase in the number of people
with LD who become seizure-free,30 the drugs have
been recommended for use in national treatment
guidelines if seizures prove refractory to ‘‘stan-
dard’’ AEDs.14
The cross tabulation of indicators of seizure
severity and epilepsy service input (Table 2) reveals
that patients with more severe and more frequent
seizures were more likely to be treated with
‘‘newer’’ AEDs or combination therapy. However,
less than 40% of those patients who had been taken
to hospital with a prolonged seizure over the last
year had access to emergency medication, and
there was no indication that patients with particu-
larly troublesome seizure disorders were more likely
to have been investigated with neuroimaging or
EEG. Given that patients under expert review were
more likely than patients under primary care review
to have had neuroimaging (see Table 1) this may be a
reflection of the fact that only a minority of patients
(even of those with refractory seizures) were seen
by epilepsy experts.
Although achieving full seizure control is only one
of many relevant positive outcomes in the lives of
people with LD and epilepsy,31 seizure-freedom is an
important treatment target and, once achieved,
can be maintained in over 80% of individuals.4 Whatis more, reports of seizure-freedom are likely to be
relatively reliable and full seizure control captures
additional benefits such as a lower risk of seizure-
related injuries and sudden unexplained death in
epilepsy (SUDEP),32 reduced risk of psychiatric
comorbidity and carer anxiety, facilitation of
school, work or care arrangements.18 The propor-
tion of individuals who achieve full seizure control is
also a measure, which allows a comparison between
an important treatment outcome of one LD epilepsy
care model with another (Table 4).
In terms of this outcome measure, the integra-
tion-oriented model examined here seemed to per-
form much less well than any other healthcare
delivery model described in the recent literature.
This is all the more striking as many of the previous
studies were based on more selected populations
likely to have included a higher proportion of people
with severe and refractory epilepsies (for instance
residents in specialist institutions or attendants of
specialist clinics). In fact, the available evidence
suggests that, with optimal medical care, at least
40% of unselected patients with LD and epilepsy
should become seizure-free.4,6
Of course, this study has a number of limitations.
Our findings are based on questionnaires completed
by carers. It is possible that respondents misunder-
stood some of the questions, rated non-epileptic
paroxysmal behaviours as manifestations of ongoing
epilepsy or failed to recollect tests, treatment
reviews or visits to specialists. It is conceivable that
carers were more likely to return the questionnaire
if the person with LD and epilepsy in their care
continued to have seizures or if they were unhappy
with the care they had received. Lastly, our analysis
is based on a very limited dataset, because we
wanted to ensure that our questionnaire was as
simple to complete as possible.
However, the extremely poor outcome in terms of
seizure-control (even compared to studies using a
90 M. Reuber et al.similar methodology or studies focussing on people
with more severe disabilities) means that there are
grounds for serious concern about the fragmentation
of healthcare services for people with LD, the lack of
access to the epilepsy specialist service, apparent
under-utilisation and suboptimal targeting of inves-
tigations, irregular critical treatment reviews, and
low levels of use of ‘‘newer’’ antiepileptic drugs. The
poor access to optimal care for people with LD and
epilepsy evident from these results may represent a
manifestation of institutional neglect,33 which has
been identified in many other areas of healthcare for
people with disabilities.34,35
Another study from the UK recently demon-
strated that expert review of individuals with epi-
lepsy (but no LD), who had not had access to
specialist advice, led to alternative diagnoses in
18.9%, and to the achievement of seizure control
in 30.9% of the patients with active epilepsy.36
Unfortunately, epilepsy experts are a very limited
resource in the UK. Although it is improbable that
major improvements could be achieved without an
expansion of specialist services, it may be more
realistic in the short term for healthcare providers
to fulfil their legal obligations under a new statutory
‘‘disability equality duty’’ by focussing on improving
referral pathways or on developing assessment
instruments which could help relatively inexper-
ienced healthcare staff to refer on those individuals
with LD and epilepsy who could benefit most from
expert assessment or investigations.37 Importantly,
such tools should not only identify individuals with
the most severe seizure disorders. The cross tabula-
tions used in this report could help to monitor the
effectiveness of policy changes.Acknowledgements
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